MDT-AP-0566
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 87.96000000000001
- os_event
- false
- age_years
- 8
- sex
- F
- new_clusters
- C3
- umap1_2d
- 3.353172103
- umap2_2d
- 2.363924236
- umap1_3d
- 0.716925541
- umap2_3d
- -2.698359356
- umap3_3d
- -2.940964354
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.470
- DNA_REPAIR+0.370
- PROTEIN_SECRETION+0.290
- MYC_TARGETS_V1+0.250
- ADIPOGENESIS+0.220
- PEROXISOME+0.200
- FATTY_ACID_METABOLISM+0.180
- HEME_METABOLISM+0.160
- PANCREAS_BETA_CELLS+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.520
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- ALLOGRAFT_REJECTION-0.470
- INFLAMMATORY_RESPONSE-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- IL2_STAT5_SIGNALING-0.380
- E2F_TARGETS-0.360
- COMPLEMENT-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0395 | Med | Medulloblastoma | 0.921 |
| 2 | BS_K74PZET7 | Med | Medulloblastoma | 0.888 |
| 3 | SRR1432321 | GTEX | — | 0.877 |
| 4 | SRR5088889 | — | — | 0.871 |
| 5 | SRR1394147 | GTEX | — | 0.869 |
| 6 | da9d049f.5aa3.4131.a2ff.092c78eed32a | — | cohortA2 | 0.868 |
| 7 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.867 |
| 8 | SRR35579848 | — | B | 0.867 |
| 9 | s0095168 | — | — | 0.864 |
| 10 | SRR1387875 | GTEX | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |